“Pharma’s topline is estimated to take a hit in the range of $258 billion over the next three years” due to expiring patents, said Arda Ural, EY Industry Markets Leader of Health Sciences and Wellness, and Big Pharma companies seem to have set money aside in preparation.
“At the beginning of 2023, Pharma held a record $1.4 trillion in its collective balance sheet to deploy toward acquisitions as needed,” Ural said. “Amid this environment, we believe this year will see more large-scale transformative dealmaking when compared to 2022.”
“This is a ‘tale of two cities’ dilemma, where the late and de-risked assets remain highly valued, while the early-phase assets face a steep discount in their valuations,” Ural said.
ONCY's platform technology in pelareorep is among the high valued, late stage and de-risked assets that Ural speaks about.